UroGen Pharma Ltd. Forecast, price target & analysts
UroGen Pharma Ltd. Target price 2025 - Analyst rating & recommendation
UroGen Pharma Ltd. Classifications & Recommendation:
UroGen Pharma Ltd. Price Target
| Target Price | $32.63 |
| Price | $9.67 |
| Potential |
237.38%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target UroGen Pharma Ltd. 2026 .
The average UroGen Pharma Ltd. target price is $32.63.
This is
237.38%
register free of charge
$55.00
468.77%
register free of charge
$16.00
65.46%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend UroGen Pharma Ltd. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the UroGen Pharma Ltd. stock has an average upside potential 2026 of
237.38%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 90.40 | 120.62 |
| 9.30% | 33.42% | |
| EBITDA Margin | -105.75% | -95.52% |
| 37.03% | 9.68% | |
| Net Margin | -138.28% | -91.21% |
| 23.71% | 34.04% |
8 Analysts have issued a sales forecast UroGen Pharma Ltd. 2025 . The average UroGen Pharma Ltd. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast UroGen Pharma Ltd. 2025 . The average UroGen Pharma Ltd. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 UroGen Pharma Ltd. Analysts have issued a net profit forecast 2025. The average UroGen Pharma Ltd. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.96 | -2.61 |
| 16.62% | 11.82% | |
| P/E | negative | |
| EV/Sales | 2.76 |
4 Analysts have issued a UroGen Pharma Ltd. forecast for earnings per share. The average UroGen Pharma Ltd. EPS is
This results in the following potential growth metrics and future valuations:
UroGen Pharma Ltd....
Current UroGen Pharma Ltd. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Apr 16 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Apr 16 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 11 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 25 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Feb 20 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
